Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

🇨🇳China

Country: 🇨🇳China

Ownership: Public, Subsidiary

Established: 2002-01-25

Employees: 1K

Market Cap: -

Website: https://www.3s-guojian.com

Clinical Trials

Evaluation of 611 in Chinese Children and Adolescents With Moderate to Severe Atopic Dermatitis

Phase 1

Not yet recruiting

Conditions: Dermatitis, Atopic

Interventions: Drug: Recombinant Anti-interleukin-4 Receptor Alpha Monoclonal Antibody Injection (611)

First Posted Date: 2024-03-22

Last Posted Date: 2024-03-22

Lead Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Target Recruit Count: 104

Registration Number: NCT06324812

Efficacy and Safety Study of 610 in Patients With Severe Asthma

Phase 3

Not yet recruiting

Conditions: Asthma

Interventions: Drug: 610
Drug: Placebo

First Posted Date: 2024-03-21

Last Posted Date: 2024-03-21

Lead Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Target Recruit Count: 480

Registration Number: NCT06323213

An Phase III Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With PsO

Phase 3

Not yet recruiting

Conditions: Plaque Psoriasis Patients

Interventions: Drug: 608 Q2W
Drug: 608 Q4W

First Posted Date: 2024-03-08

Last Posted Date: 2024-03-08

Lead Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Target Recruit Count: 750

Registration Number: NCT06299982

A Study of SSGJ-613 in Gout Subjects Initiating Urate-Lowering Treatment.

Phase 2

Active, not recruiting

Conditions: Gout Arthritis

Interventions: Drug: Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 100 mg
Drug: Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg
Drug: Colchicine 0.5 mg

First Posted Date: 2024-02-21

Last Posted Date: 2024-08-05

Lead Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Target Recruit Count: 157

Registration Number: NCT06270225

Locations: 🇨🇳
Shanghai Huashan Hospital Fudan University-Rheumatology, Shanghai, Shanghai, China

A Study to Evaluate 608 in Patients with Ankylosing Spondylitis (AS)

Phase 2

Active, not recruiting

Conditions: Ankylosing Spondylitis

Interventions: Drug: Placebo
Drug: 608 Dose A
Drug: 608 Dose B
Drug: 608 Dose C
Drug: Adalimumab

First Posted Date: 2024-02-05

Last Posted Date: 2024-10-23

Lead Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Target Recruit Count: 250

Registration Number: NCT06242652

Locations: 🇨🇳
Site 01, Beijing, Beijing, China

A Study to Evaluate 608 in Patients With Non- Radiographic Axial Spondyloarthritis (Nr-axSpA)

Phase 2

Not yet recruiting

Conditions: Axial Spondyloarthritis

Interventions: Drug: 608
Drug: Placebo

First Posted Date: 2024-01-25

Last Posted Date: 2024-01-25

Lead Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Target Recruit Count: 180

Registration Number: NCT06222671

Locations: 🇨🇳
Site 02, Zhengzhou, Henan, China
🇨🇳
Site 04, Nanjing, Jiangsu, China
🇨🇳
Site 03, Beijing, Beijing, China

and more 3 locations

Evaluation of 611(Recombinant Humanized Anti-interleukin-4 Receptor Alpha IgG4 Monoclonal Antibody) in Chinese Adults With Moderate to Severe Atopic Dermatitis

Phase 3

Recruiting

Conditions: Dermatitis, Atopic

Interventions: Drug: 611
Drug: Matching placebo

First Posted Date: 2023-12-15

Last Posted Date: 2024-02-01

Lead Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Target Recruit Count: 510

Registration Number: NCT06173284

Locations: 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
🇨🇳
Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
🇨🇳
The Fourth Affiliated Hospital Zhejiang University School of Medicine, Jinhua, Zhejiang, China

and more 1 locations

A Study of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection in Chinese Participants With Acute Gout

Phase 3

Not yet recruiting

Conditions: Acute Gout

Interventions: Drug: Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg
Drug: Compound Betamethasone Injection
Other: Placebo

First Posted Date: 2023-12-14

Last Posted Date: 2023-12-14

Lead Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Target Recruit Count: 500

Registration Number: NCT06169891

Evaluation of 611 in Chinese Adults With Moderate to Severe Chronic Obstructive Pulmonary Disease

Phase 2

Recruiting

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: 611 450 mg Q2W
Drug: Matching placebo
Drug: 611 300 mg Q2W

First Posted Date: 2023-10-25

Last Posted Date: 2024-02-01

Lead Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Target Recruit Count: 150

Registration Number: NCT06099652

Locations: 🇨🇳
China-Japan Friendship Hospital, Beijing, Beijing, China
🇨🇳
Shenzhen People's Hospital, Shenzhen, Guangdong, China
🇨🇳
Zhongshan Hospital affiliated to Fudan University, Shanghai, Shanghai, China

The MAD Study of SSGJ-613 in Healthy Subjects

Phase 1

Not yet recruiting

Conditions: Arthritis, Gouty

Interventions: Drug: SSGJ-613
Drug: Placebo

First Posted Date: 2023-08-01

Last Posted Date: 2023-08-01

Lead Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Target Recruit Count: 36

Registration Number: NCT05966701

Locations: 🇨🇳
Shanghai Xuhui District Central Hospital, Shanghai, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy